Apixaban superior to warfarin across range of patient risk scores
A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, according to Duke University Medical Center researchers.
Their results, published online today in The Lancet, suggest that the current risk scoring systems for tailoring anticoagulation treatment to individual patients may be less relevant when using apixaban for patients with atrial fibrillation who have at least one risk factor for stroke.
"The benefits of apixaban are preserved regardless of the risk score used and regardless of the patient risk category," said Renato Lopes, M.D., a Duke cardiologist and the lead author of the study. Importantly, apixaban was safer than warfarin in the overall population and tended to cause less intracranial bleeding in those patients whose risk scores defined them as being at the highest risk of bleeding.
"With new oral anticoagulants, such as apixaban, we might not need risk scores to guide treatment decisions for stroke prevention in patients with atrial fibrillation. This may simplify how physicians make decisions and also improve patient care," Lopes said.
Practice guidelines have allowed use of either antithrombotic therapy with warfarin or with aspirin, which is less effective but has lower risk of bleeding, for patients with atrial fibrillation and one risk factor for stroke. Apixaban, with better prevention of stroke and lower risk of bleeding than warfarin, may remove aspirin as an attractive option for this group of patients.
Atrial fibrillation is a common abnormal heart rhythm that affects more than 2.6 million people in the United States. It occurs when the heart's electrical activity becomes disorganized, resulting in an irregular heartbeat with ineffective contraction of the upper chambers of the heart. The potential for blood clots to form, and one's risk for stroke, increases as a result.
Risk scores for bleeding and thromboembolism (blood clots) have been used to predict the risk of these events to guide use of warfarin, a vitamin K antagonist that is standard treatment to help prevent stroke and blood clots. Only about half of patients who could benefit from warfarin actually do because the drug has several limitations, including a requirement for regular monitoring and increased bleeding risk such as intracranial hemorrhage.
Apixaban is an oral direct factor Xa inhibitor that has already been shown to be safer and more effective than warfarin for patients with atrial fibrillation. Last year, Duke researchers presented the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial at the European Society of Cardiology. It showed apixaban resulted in an additional 21 percent relative reduction in stroke or systemic embolism when compared to warfarin, a 31 percent relative reduction in major bleeding, and an 11 percent relative reduction in overall mortality.
The analysis published in The Lancet used the ARISTOTLE data to assess safety and efficacy of apixaban versus warfarin in 18,201 patients based on the most popular risk assessment scores. CHADS2, CHA2DS2VASc, and HAS-BLED are used to estimate risk of stroke and bleeding in patients with atrial fibrillation and help guide warfarin treatment decisions.
"Risk stratification has been a key element in identifying patients at risk for stroke and bleeding and in helping to guide antithrombotic treatment for patients with atrial fibrillation," Lopes said. "However, most of patients at high risk for stroke are also at high risk for bleeding. This makes the treatment of these patients a challenge in clinical practice.
"Our study shows that irrespective of the risk of stroke or bleeding, apixaban is more effective and safer than warfarin across all patients with atrial fibrillation and at least one additional risk factor for stroke," Lopes said. "Thus, the current risk scores used in clinical practice for patients with atrial fibrillation may play less of a role in decision-making because we now have more efficacious and safer drugs."
Journal reference:
The Lancet
Provided by
Duke University Medical Center
-
Apixaban superior to warfarin for preventing stroke, reducing bleeding and saving lives
Aug 28, 2011 |
not rated yet |
0
-
Chronic kidney disease increases stroke risk in A-fib
Aug 16, 2012 |
not rated yet |
0
-
Success stops drug trial
Aug 31, 2010 |
not rated yet |
0
-
More advantages found for new drug: study
Feb 10, 2011 |
not rated yet |
0
-
Blood-Thinning Drug Linked to Increased Bleeding in Brain
Sep 29, 2008 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
the rudyak-krasnolutski effective potencial
55 minutes ago
-
Normal force for a lever model
2 hours ago
-
gravity is std. therefore can we rate a 'mass at height' by watts?
7 hours ago
-
Calculating on-axis elements of a solenoid
19 hours ago
-
latitude & longitude & air pressure
20 hours ago
-
Differences of Classical Mechanics when learned with Calc vs algebra?
May 22, 2013
- More from Physics Forums - Classical Physics
More news stories
Death rates decline for advanced heart failure patients, but outcomes are still not ideal
UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden ...
Cardiology
52 minutes ago |
not rated yet |
0
Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II
22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...
Cardiology
5 hours ago |
not rated yet |
0
Costs to treat stroke in America may double by 2030
Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.
Cardiology
May 22, 2013 |
not rated yet |
0
New blood-thinner measures may cut medication errors
Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...
Cardiology
May 22, 2013 |
not rated yet |
0
Registry questions superiority of bivalirudin over heparin
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...
Cardiology
May 22, 2013 |
5 / 5 (1) |
0
Diabetes' genetic underpinnings can vary based on ethnic background, studies say
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
Scientists discover cinnamon compounds' potential ability to prevent Alzheimer's
Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of –– or warding off ...
Ferrets, pigs susceptible to H7N9 avian influenza virus
Chinese and U.S. scientists have used virus isolated from a person who died from H7N9 avian influenza infection to determine whether the virus could infect and be transmitted between ferrets. Ferrets are often used as a mammalian ...
Study reveals new mechanism for estrogen suppression of liver lipid synthesis
By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.
MRI-based measurement helps predict vascular disease in the brain
Aortic arch pulse wave velocity, a measure of arterial stiffness, is a strong independent predictor of disease of the vessels that supply blood to the brain, according to a new study published in the June issue the journal ...
Second child contracts polio in Pakistan's Waziristan
A second child has contracted polio in a restive Pakistani tribal region near the Afghan border after the Taliban banned vaccinations there nearly a year ago, a UN official said Thursday.